Fri.Jun 06, 2025

article thumbnail

COVID-19 Vaccine Recommendations Spark Confusion and Trust Concerns, Experts Warn

Drug Topics

Lauren Angelo, PharmD, MBA, associate dean of academic affairs at Rosalind Franklin University of Medicine and Science, highlights significant concerns about the evolving landscape of COVID-19 vaccine policy.

Vaccines 436
article thumbnail

With ADCs on the rise, drugmakers embrace a new oncology pillar

PharmaVoice

Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Passport to Protection: Best Practices for Travel Vaccines in the Pharmacy Setting

Drug Topics

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

Vaccines 341
article thumbnail

When Placebo Plus Standard of Care Clouds the Signal: Unmasking the “Placebo Problem” in Lupus Clinical Trials

Pharmacy Times

Juan Ovalles, MD, PhD, discusses how high placebo response rates driven by background therapy complicate lupus drug trials, and outlines evolving strategies in trial design, clinical practice, and pharmacist-led care to ensure investigational biologics are fairly evaluated and appropriately used in systemic lupus erythematosus.

119
119
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

TikTok Videos on IBD Provide Low Quality Information

Drug Topics

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

FDA 281
article thumbnail

STAT+: Otsuka tops Vera Therapeutics in kidney disease study showdown

STAT

A monthly treatment from Otsuka reduced by more than half the levels of a toxic protein in the urine of patients with an autoimmune kidney disease. The results presented Friday achieved the interim goal of a Phase 3 study and were numerically superior to study results posted Monday by competitor Vera Therapeutics.  The Otsuka drug, called sibeprenlimab, lowered proteinuria levels by 50.2% after nine months compared to an increase of 2.1% in patients given a placebo.

91

More Trending

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

How data-driven partnerships and precision engagement are redefining pharma's role in patient care

article thumbnail

Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression

Pharmacy Times

Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.

article thumbnail

RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity

Pharmacy Times

Subcutaneous immunoglobulin was found to elicit fewer viral infections compared with other routes of immunoglobulin replacement therapy, including intravenous immunoglobulin.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Osivax reaches key milestone in phase 2a trial for broad-spectrum flu vaccine

Pharmafile

Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a broad-spectrum influenza A vaccine candidate. The final results from the trial are expected in the second half of 2025. Conducted at the centre for vaccinology (CEVAC), Ghent University Hospital, Belgium, the trial investigated the safety […] The post Osivax reaches key milestone in phase 2a trial for broad-spectrum flu vaccine appeared first on Pharmafile.

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.

75
article thumbnail

GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes

Pharmacy Times

Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.

73
article thumbnail

Five for Friday June 6: Celebrating Success in Advancing Medication Use Quality

PQA

Welcome to Five For Friday! Nearly 400 leaders from PQA member organizations attended the 2025 PQA Annual Meeting, May 19-21, to network, engage and gain actionable insights. Attendees heard from more than 60 speakers across the general sessions, breakout sessions, briefing sessions and innovation theaters. During the meeting, PQA presented eight Medicare plan contracts with a PQA Laura Cranston Excellence in Quality or Quality Improvement Award and awarded top posters from the 2025 PQA Annual M

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Bayer trial combines two top drugs for kidney disease

pharmaphorum

Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics

59
article thumbnail

Wegovy vs. Mounjaro side effects

The Checkup by Singlecare

Wegovy (semaglutide) and Mounjaro (tirzepatide) are both prescription drugs that help regulate blood sugar and decrease appetite. However, the Food and Drug Administration (FDA) has approved them for different purposes: Wegovy is approved as a weight loss medication, and Mounjaro is approved as a Type 2 diabetes treatment. Mounjaro’s active ingredient, tirzepatide, is sold as an FDA-approved weight loss drug under the name Zepbound.

Dosage 52
article thumbnail

Digital health firm Omada prices $150m IPO

pharmaphorum

In another sign of recovery in digital health investing, Omada Health has priced an IPO that could value the company at more than $1.

94
article thumbnail

Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics

Pharmacy Times

New research analyzes human challenge infection studies to reveal insights on respiratory syncytial virus viral load and symptom dynamics, aiding treatment development.

73
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

AZ claims EU approval for new Calquence regimens in CLL

pharmaphorum

AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa

84
article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

In the study, diabetes patients who took GLP-1s were twice as likely to develop neovascular age-related macular degeneration (nAMD) than those without GLP-1 exposure.

81
article thumbnail

EC authorises Sydnexis’ paediatric myopia treatment

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

Mapping the Hidden Costs

Pharmaceutical Commerce

In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s data reveals about the relationship between pharmacy access and broader health disparities in underserved communities.

52
article thumbnail

Can I start Wegovy at 1.7 mg?

The Checkup by Singlecare

Wegovy is a GLP-1 receptor agonist that contains the active ingredient semaglutide. Developed by Novo Nordisk, this prescription drug has transformed weight loss treatment options for many people with obesity. It comes as a once-weekly injection and works by mimicking a natural hormone that regulates appetite and blood sugar levels. Based on clinical trials, the Food and Drug Administration (FDA) has approved Wegovy as a go-to option for those struggling with weight management.

Dosage 52
article thumbnail

SCHOTT Pharma invests in RTU cartridge capacity expansion

Pharmaceutical Technology

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

DeepIntent’s Jay Richetelli discusses the role of AI, data ownership and trust in shaping the next era of pharma marketing

59
article thumbnail

Duchenne gene therapy interim trial outcomes “striking”

European Pharmaceutical Review

New positive interim trial data has demonstrated that a potential best-in-class gene therapy can provide meaningful functional improvements in Duchenne muscular dystrophy. These new findings are from the Phase I/II AFFINITY DUCHENNE clinical trial for RGX-202. With a differentiated microdystrophin construct, the treatment can encode key regions of naturally occurring dystrophin, including the C-Terminal (CT) domain.

article thumbnail

Sequencing Strategies and the Role of Combination Therapy

Pharmacy Times

Panelists discuss how evolving treatment pathways at Emory Healthcare, including earlier use of emerging therapies and off-label combination treatments, are shaping the management of chronic graft-vs-host disease (cGVHD), with an emphasis on personalizing therapy based on real-world data and patient-specific factors.

article thumbnail

Wegovy vs. Mounjaro cost comparison

The Checkup by Singlecare

Wegovy (semaglutide) and Mounjaro (tirzepatide) are both brand-name injectable medications that regulate blood sugar levels and suppress appetite. Both have gained attention for their weight loss potential, but only Wegovy is approved by the Food and Drug Administration (FDA) specifically for weight management. Because of these drugs’ popularity and similarities, some people may wonder if one is significantly more expensive than the other.

article thumbnail

Trial into rare genetic disease Werner syndrome reports promising results

Pharmafile

Researchers at Chiba University, Japan, alongside Niagen Bioscience, have reported successful results from the world’s first trial of nicotinamide riboside (NR), vitamin B3 derivative, for the treatment of Werner syndrome (WS), a rare genetic disorder. The study found that it enhances cardiovascular, skin and kidney health in patients, offering treatment potential for a disease which […] The post Trial into rare genetic disease Werner syndrome reports promising results appeared first on Ph

59
article thumbnail

Will insurance cover Ozempic for fatty liver?

The Checkup by Singlecare

Ozempic (semaglutide) is a glucagon-like peptide-1 receptor (GLP-1) agonist taken as a weekly injection that’s approved by the Food and Drug Administration (FDA) to improve blood sugar control in adults with Type 2 diabetes, reduce the risk of stroke and heart attack in adults with Type 2 diabetes and cardiovascular disease, and help with slowing the progression of kidney disease in people with Type 2 diabetes and chronic kidney disease.

article thumbnail

BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours

Pharmafile

BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to treat multiple solid tumour types. BNT327 targets two established immuno-oncology pathways, PD-L1 and VEGF-A, to enhance tumour targeting and modulate the tumour microenvironment. It is currently in phase 3 trials for small cell and non-small […] The post BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumo

64
article thumbnail

How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging

PharmTech

Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.